Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers may leads to lower cardiovascular mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
It is very uncertain whether beta‐blockers changes heart failure hospitalisation (RR) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
All‐cause mortality at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
Beta‐blockers showed no clear difference in all‐cause mortality at 'less than 3 months' compared with placebo or no intervention (high certainty).
1 finding from 1 review
MACE · patients with suspected or diagnosed myocardial infarction
It is very uncertain whether beta‐blockers changes MACE (major adverse cardiovascular event) at maximum compared with placebo or no intervention (very low certainty).
2 findings from 1 review
Quality of life at maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Angina · patients with suspected or diagnosed myocardial infarction
It is very uncertain whether beta‐blockers changes angina at maximum compared with placebo or no intervention (very low certainty).
2 findings from 1 review
Cardiovascular mortality · patients with suspected or diagnosed myocardial infarction
Beta‐blockers probably leads to lower cardiovascular mortality at maximum compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
Myocardial infarction · patients with suspected or diagnosed myocardial infarction
Beta‐blockers showed no clear difference in myocardial infarction at maximum compared with placebo or no intervention (low certainty).
2 findings from 1 review
Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · patients with suspected or diagnosed myocardial infarction
Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · people with confirmed diagnosis of Marfan syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in all‐cause mortality compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Clinically important non‐fatal end point as defined byShores 1994(aortic dissection, aortic regurgitation, congestive heart failure, or cardiovascular surgery) · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in clinically important non‐fatal end point as defined byShores… compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Acute aortic dissection · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in acute aortic dissection compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Aortic regurgitation · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in aortic regurgitation compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review